- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.10. | 1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data | 2 | MarketBeat | ||
| 28.10. | Incyte trims pipeline; Zenas surges on MS drug results | 9 | BioPharma Dive | ||
| 28.10. | Zenas Biopharma stock price target raised to $44 at H.C. Wainwright | 1 | Investing.com | ||
| 27.10. | Zenas Biopharma: Morgan Stanley erhöht Kursziel nach vielversprechenden Studiendaten zu MS-Medikament | 3 | Investing.com Deutsch | ||
| 27.10. | Zenas Biopharma stock price target raised by Morgan Stanley on MS drug data | 2 | Investing.com | ||
| 27.10. | Jefferies erhöht Kursziel für Zenas Biopharma nach starken Studiendaten auf 52 US-Dollar | 1 | Investing.com Deutsch | ||
| 27.10. | Jefferies raises Zenas Biopharma stock price target to $52 on strong trial data | 1 | Investing.com | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 27.10. | Zenas' lead autoimmune drug prompts 95% reduction in new brain lesions in phase 2 MS study | 1 | FierceBiotech | ||
| 27.10. | Zenas BioPharma stock soars after positive MS drug trial results | 1 | Investing.com | ||
| 27.10. | Zenas BioPharma: Aktie steigt nach positiven Studiendaten zu MS-Medikament um 80 % | 1 | Investing.com Deutsch | ||
| 27.10. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.10. | Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis | 424 | GlobeNewswire (Europe) | - Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas... ► Artikel lesen | |
| 21.10. | Zenas BioPharma files to sell 6.31M shares of common stock for holders | 4 | Seeking Alpha | ||
| 10.10. | Hedge Fund and Insider Trading News: Jeffrey Ubben, Ken Griffin, Chris Hohn, Bill Ackman, Scott Bessent, Alden Global Capital, Balyasny Asset Management, Eisler Capital, Zenas Biopharma Inc (ZBIO), Dell Technologies Inc (DELL), and More | 13 | Insider Monkey | ||
| 10.10. | Fierce Pharma Asia-TROP2 showdown; InnoCare, Zenas' $2B autoimmune deal; Lupin's US investment | 2 | FiercePharma | ||
| 09.10. | Zenas BioPharma rises after Wedbush raises price target | 5 | Seeking Alpha | ||
| 09.10. | H.C. Wainwright maintains Zenas Biopharma stock Buy rating on pipeline expansion | 2 | Investing.com | ||
| 09.10. | China's InnoCare Plunges After Granting Overseas Rights for Three Innovative Drugs to US Peer Zenas | 1 | Yicai Global | ||
| 08.10. | Zenas BioPharma files automatic mixed securities shelf | 1 | Seeking Alpha | ||
| 08.10. | Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug | 1 | Benzinga.com |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 292,10 | -0,03 % | Märkte am Morgen: AMD, Uber, Super Micro Computer, Amgen, Qiagen | Nach dem starken Monatsauftakt hat der DAX spürbar an Schwung verloren. Der Leitindex fiel am Dienstag zeitweise um zwei Prozent, konnte sich aber leicht erholen und schloss 0,76 Prozent tiefer bei... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 582,00 | -0,03 % | Regeneron Reports Promising Phase 2 Results For Novel Factor XI Antibodies In Knee Surgery Patients | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from two Phase 2 clinical trials evaluating its investigational factor XI antibodies-REGN7508Cat and... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 48,050 | +1,35 % | Stifel stuft BioMarin-Aktie wegen Sorgen um Voxzogo auf "Halten" herab | ||
| ARROWHEAD PHARMACEUTICALS | 35,600 | -0,61 % | Arrowhead Pharmaceuticals vor FDA-Entscheidung: Attraktive Kaufchance? | Arrowhead Pharmaceuticals steht kurz vor entscheidenden Weichenstellungen, die den langfristigen Erfolg des Unternehmens maßgeblich beeinflussen könnten. Rückenwind gibt's aktuell durch einen starken... ► Artikel lesen | |
| INSMED | 169,00 | +0,60 % | Insmed Incorporated: Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update | -BRINSUPRI (brensocatib) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European Union... ► Artikel lesen | |
| SWEDISH ORPHAN BIOVITRUM | 30,880 | +1,71 % | Swedish Orphan Biovitrum AB: Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions |
STOCKHOLM, Nov. 8, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that, the TIMI Study Group today has presented positive results from the pivotal Phase 3 CORE and CORE2 studies... ► Artikel lesen | |
| SCHOLAR ROCK | 27,000 | +1,50 % | Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference | Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe... ► Artikel lesen | |
| PROQR THERAPEUTICS | 1,900 | +1,88 % | ProQR Therapeutics N.V.: ProQR Announces Third Quarter 2025 Operating and Financial Results | Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 37,000 | -0,54 % | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VENTYX BIOSCIENCES | 9,430 | 0,00 % | Ventyx Biosciences, Inc.: Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress | Data from the recent Phase 2 study position Ventyx's NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomarker... ► Artikel lesen | |
| THERATECHNOLOGIES | 2,780 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 06.10.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 06.10.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 06.10.2025.ISIN NameAT0000A3PGY9 UBM... ► Artikel lesen | |
| ENSYSCE BIOSCIENCES | 2,030 | 0,00 % | Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025 | ~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / October 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 40,630 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| TEVOGEN BIO | 0,440 | +8,64 % | Tevogen Bio Inc: Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID | This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,70 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen |
Das Unternehmen ZENAS BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 35,130 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.